683 Capital Management LLC Buys New Shares in Emergent BioSolutions Inc. (NYSE:EBS)

683 Capital Management LLC acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 92,691 shares of the biopharmaceutical company's stock, valued at approximately $886,000. 683 Capital Management LLC owned about 0.17% of Emergent BioSolutions as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC boosted its stake in Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock valued at $329,000 after purchasing an additional 30,792 shares during the period. Geode Capital Management LLC boosted its holdings in Emergent BioSolutions by 4.6% during the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock worth $4,861,000 after buying an additional 25,776 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Emergent BioSolutions by 41.7% in the 4th quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock worth $2,928,000 after acquiring an additional 90,113 shares during the last quarter. Invesco Ltd. increased its stake in Emergent BioSolutions by 70.9% in the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock worth $14,722,000 after purchasing an additional 638,995 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Emergent BioSolutions by 3.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock valued at $7,328,000 after acquiring an additional 24,985 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares of the company's stock, valued at $589,413. The trade was a 25.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EBS. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, April 1st. StockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Stock Up 0.9 %

Shares of Emergent BioSolutions stock traded up $0.04 on Wednesday, hitting $4.83. 305,788 shares of the company traded hands, compared to its average volume of 1,932,535. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 12-month low of $3.91 and a 12-month high of $15.10. The company has a 50-day moving average price of $5.21 and a 200 day moving average price of $7.98. The company has a market cap of $262.50 million, a PE ratio of -1.18 and a beta of 2.09.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period last year, the business earned ($0.77) EPS. Sell-side analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its Board of Directors has approved a stock buyback program on Monday, March 31st that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.